Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX-531 in Advanced Solid Tumors
NCT07874880Phase 1Not yet recruiting
- Sponsor
- MEKanistic Therapeutics
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MTX-531 in solid tumor, endometrial cancer (EC), breast cancer and 2 more, sponsored by MEKanistic Therapeutics. Primary endpoints: Safety and Tolerability profile of MTX-531 at 21 days and Provisional Recommended Phase 2 Dose at 30 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
MTX-531
03
Conditions
solid tumorendometrial cancer (EC)breast cancercolorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07874880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07874880.